Biblio
Export 417 results:
Author Title Type Year Filters: First Letter Of Keyword is S [Clear All Filters]
“TREM2 variants in Alzheimer's disease.”, N Engl J Med, vol. 368, no. 2, pp. 117-27, 2013.
, “Geographical Distribution and Diversity of Gut Microbial NADH:Ubiquinone Oxidoreductase Sequence Associated with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1531-1540, 2018.
, “Assessing Working Memory in Mild Cognitive Impairment with Serial Order Recall.”, J Alzheimers Dis, vol. 61, no. 3, pp. 917-928, 2018.
, “Propagation of tau pathology in a model of early Alzheimer's disease.”, Neuron, vol. 73, no. 4, pp. 685-97, 2012.
, “GSK-3β is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner.”, J Alzheimers Dis, vol. 49, no. 2, pp. 365-75, 2016.
, “SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion.”, J Alzheimers Dis, vol. 61, no. 2, pp. 561-570, 2018.
, “Lack of evidence for a role of HHV-6 in the pathogenesis of Alzheimer's disease.”, J Alzheimers Dis, vol. 49, no. 1, pp. 229-35, 2016.
, “Memory impairment in transgenic Alzheimer mice requires cellular prion protein.”, J Neurosci, vol. 30, no. 18, pp. 6367-74, 2010.
, “Investigating Casual Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases: A Mendelian Randomization Study.”, J Alzheimers Dis, vol. 87, no. 1, pp. 211-222, 2022.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.”, J Alzheimers Dis, vol. 50, no. 3, pp. 733-40, 2016.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin.”, J Alzheimers Dis, vol. 61, no. 1, pp. 321-332, 2018.
, “Dose-Dependent Neuroprotection and Neurotoxicity of Simvastatin through Reduction of Farnesyl Pyrophosphate in Mice Treated with Intracerebroventricular Injection of Aβ 1-42.”, J Alzheimers Dis, vol. 50, no. 2, pp. 501-16, 2016.
, “Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 1, pp. 283-95, 2016.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.
, “Validation of the Spanish version of the Baylor Profound Mental Status Examination.”, J Alzheimers Dis, vol. 49, no. 1, pp. 73-8, 2016.
, “Cost Related to Dementia in the Young and the Impact of Etiological Subtype on Cost.”, J Alzheimers Dis, vol. 49, no. 2, pp. 277-85, 2016.
, “Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 49, no. 4, pp. 927-43, 2016.
, “Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1085-93, 2016.
, “Impaired Parahippocampus Connectivity in Mild Cognitive Impairment and Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1051-64, 2016.
, “Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk Score.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1169-77, 2016.
, “Heterogeneity of Cognitive Anosognosia and its Variation with the Severity of Dementia in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 1, pp. 89-99, 2016.
,